香港举办了一场生物技术展览,突出了主要的交易和批准,加强其作为全球医疗科技中心的起. Hong Kong hosted a biotech showcase highlighting major deals and approvals, reinforcing its rise as a global health tech hub.

2026年3月18日,香港科技园区公司举办了CTC市场展示活动,吸引110名生命和健康技术领导者,投资者和合作伙伴来强调香港在生物技术创新中的不断增长的作用. On March 18, 2026, Hong Kong Science and Technology Parks Corporation hosted the CTC Marketplace Showcase Event, drawing 110 life and health tech leaders, investors, and partners to highlight Hong Kong’s rising role in biotech innovation. 活动展示了关键的里程碑,包括潜在的825万美元许可协议,15300万美元E轮融资,150亿美元收购以及香港首次在1+机制下批准COPD药物. The event showcased key milestones, including a potential $82.5 million licensing deal, a $153 million Series E funding round, a $1.5 billion acquisition, and Hong Kong’s first approval under the “1+” mechanism for a COPD drug. 超过300家生命和健康科技公司在HKSTP的生态系统中运营,该生态体系提供基础设施,资金,监管指导以及支持全球市场准入,并得到强有力的政府政策支持. Over 300 life and health tech companies operate within HKSTP’s ecosystem, which provides infrastructure, funding, regulatory guidance, and global market access support, backed by strong government policy. 活动强调了香港医疗技术中心在加速研究商业化,临床试验和筹款方面的成功,加强了香港作为全球医学创新枢纽的地位. The event underscored HKSTP’s success in accelerating research commercialization, clinical trials, and fundraising, reinforcing Hong Kong’s growing position as a global hub for medical innovation.